{
  "id": "61f7ceeb882a024a1000002e",
  "type": "list",
  "question": "What are the targets of Tirbanibulin?",
  "ideal_answer": "Tirbanibulin is Src kinase signaling inhibitor and tubulin polymerisation inhibitor that is being developed for the topical treatment of actinic keratosis, and psoriasis.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/33713299",
    "http://www.ncbi.nlm.nih.gov/pubmed/33196758",
    "http://www.ncbi.nlm.nih.gov/pubmed/33567191",
    "http://www.ncbi.nlm.nih.gov/pubmed/34349652",
    "http://www.ncbi.nlm.nih.gov/pubmed/34783452"
  ],
  "snippets": [
    {
      "text": "BACKGROUND: The tubulin polymerization and Src kinase signaling inhibitor tirbanibulin is being investigated as a topical treatment for actinic keratosis, a precursor of squamous-cell carcinoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33567191",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tirbanibulin (Klisyri\u00ae) is a first-in-class Src kinase signaling inhibitor and tubulin polymerisation inhibitor being developed by Athenex in conjunction with global partners for the topical treatment of actinic keratosis, and psoriasis. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33713299",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tirbanibulin is a novel tubulin polymerization and Src kinase signaling inhibitor.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34783452",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tirbanibulin (KX-01) is the first clinical Src inhibitor of the novel peptidomimetic class that targets the peptide substrate site of Src providing more specificity toward the Src kinase. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34349652",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tirbanibulin (Klisyri\u00ae) is a first-in-class Src kinase signaling inhibitor and tubulin polymerisation inhibitor being developed by Athenex in conjunction with global partners for the topical treatment of actinic keratosis, and psoriasis. Based on the data fro",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33713299",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tirbanibulin, a novel potent anti-proliferative synthetic agent that inhibits tubulin polymerization and Src kinase signalling, is being developed as a convenient, safe, and effective field treatment of actinic keratosis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33196758",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tirbanibulin (KX-01) is the first clinical Src inhibitor of the novel peptidomimetic class that targets the peptide substrate site of Src providing more specificity toward the Src kinase.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34349652",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tirbanibulin is a novel tubulin polymerization and Src kinase signaling inhibitor",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34783452",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "atment. Tirbanibulin, a novel potent anti-proliferative synthetic agent that inhibits tubulin polymerization and Src kinase signalling, is being developed as a convenient, safe, and effective field treatment of actinic kerat",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33196758",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tirbanibulin (Klisyri\u00ae) is a first-in-class Src kinase signaling inhibitor and tubulin polymerisation inhibitor being developed by Athenex in conjunction with global partners for the topical treatment of actinic keratosis, and psoriasis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33713299",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: The tubulin polymerization and Src kinase signaling inhibitor tirbanibulin is being investigated as a topical treatment for actinic keratosis, a precursor of squamous-cell carcinoma.METHODS: In two identically designed double-blind trials, we randomly assigned, in a 1:1 ratio, adults with actinic keratoses on the face or scalp to receive either topical tirbanibulin or vehicl",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33567191",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Src kinase signaling, tubulin polymerisation"
}